Resmed Inc (RMD) Q3 2020 Earnings Call Transcript

Resmed Inc (RMD) Q3 2020 Earnings Call Transcript

I will now turn the call over to Amy Wakeham, Vice President of Investor Relations and Corporate Communications.. We have accelerated production and distribution of invasive ventilators, noninvasive ventilators, including bilevel devices as well as ventilation masks for the patients who need them most, no matter where they live.. We produced over 52,000 noninvasive ventilators, including bilevels and invasive ventilators during the quarter.. We have also driven a tenfold increase in our ventilation mask production, actually more than tenfold.. We are aligning distribution of these ventilation products worldwide using a global ethical epidemiology-based model of ventilation needs based on our models of the surge of COVID-19 patients around the world.. And today, more than ever, these capabilities enable us at ResMed to support our customers with a sustainable supply of products, services and solutions throughout this COVID-19 crisis and beyond.. We have over 13 million patients as well as over six billion nights, six billion nights of respiratory medical data in the cloud.. Digital health also brings benefits of more scalability, more cost efficiency and better outcomes for patients.. We have delivered strong growth in our sleep apnea, COPD and asthma businesses across geographies, with solid contributions from our software-as-a-service